Related Experiment Video
Updated: Jul 2, 2026
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Budesonide/Formoterol pressurized metered-dose inhaler.
Katherine A Lyseng-Williamson1, Dene Simpson
1Wolters Kluwer Health | Adis, Auckland, New Zealand. demail@adis.co.nz
Drugs
|August 30, 2008
Summary
A new combination inhaler with budesonide and formoterol (pMDI) significantly improved lung function and asthma control in patients aged 12 years and older. This asthma treatment was well-tolerated and showed benefits over placebo and monotherapy.
Area of Science:
- Respiratory Medicine
- Pharmacology
Background:
- Asthma management often involves inhaled corticosteroids and long-acting beta2-adrenoceptor agonists.
- Combining these therapies into a single inhaler may improve patient adherence and treatment efficacy.
Purpose of the Study:
- To evaluate the efficacy and safety of a budesonide/formoterol combination pressurized metered-dose inhaler (pMDI) in asthma patients.
- To compare the budesonide/formoterol pMDI with placebo and monotherapy with its individual components.
Main Methods:
- 12-week clinical trials were conducted in patients aged >=12 years with mild-to-moderate or moderate-to-severe persistent asthma.
- Patients received twice-daily budesonide/formoterol pMDI (160mcg/9mcg or 320mcg/9mcg), placebo, or monotherapy.
- A 52-week safety study compared budesonide/formoterol pMDI (320mcg/9mcg) with budesonide pMDI (640mcg) monotherapy.
Main Results:
- Twice-daily budesonide/formoterol pMDI significantly improved lung function compared to placebo and monotherapy.
- Patient-reported outcomes, including asthma control and quality of life, showed significant improvements with the combination inhaler.
- The 52-week study demonstrated rapid and sustained improvements in lung function and asthma control with budesonide/formoterol pMDI.
Conclusions:
- Budesonide/formoterol pMDI is an effective treatment for asthma in patients aged 12 years and older.
- The combination inhaler offers significant benefits in lung function and asthma control compared to placebo and monotherapy.
- Budesonide/formoterol pMDI was well-tolerated, with an adverse event profile consistent with known therapies.
Related Concept Videos
01:23Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...